Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ziritaxestat DDI with Itraconazole and Voriconazole
NCT03515382Phase 1Completed
- Sponsor
- Galapagos NV
- Start
- Mar 2018
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ziritaxestat in idiopathic pulmonary fibrosis (IPF) (3 arms), sponsored by Galapagos NV. Primary endpoints: Maximum observed plasma concentration, Area under the plasma concentration-time curve from time zero to infinity and 1 more. Started Mar 2018; status: completed.
02
Drugs
ziritaxestat
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT03515382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03515382.